GlassScriptPhysician profile
Stacy L Dycus
NPI 1710529136
$8,217.30
in general payments reported to CMS, 2019-2025
23 companies · $2,161 in 2025
The $2,161 reported for 2025 was more than what 93% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $984 · 2022: $1,308 · 2023: $1,754 · 2024: $2,010 · 2025: $2,161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,775 · Education: $151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,774.71 |
| Education | $150.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $1,252.60 | 2021-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $961.68 | 2021-2025 | Invega Sustenna, Spravato |
| Abbvie INC. | $944.68 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $930.07 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Neurocrine Biosciences, INC. | $751.04 | 2021-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $669.22 | 2021-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $559.33 | 2021-2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $519.16 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Supernus Pharmaceuticals, INC. | $475.77 | 2023-2024 | Qelbree, Qelbree |
| E.R. Squibb & Sons, L.L.C. | $384.00 | 2024-2025 | Cobenfy |
| Corium, LLC | $149.57 | 2023-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $139.63 | 2022-2024 | Jornay Pm |
| Axsome Therapeutics, INC. | $120.61 | 2023-2025 | Auvelity |
| Sunovion Pharmaceuticals INC. | $82.48 | 2021 | |
| Noven Therapeutics, LLC | $59.34 | 2025 | Secuado, Xelstrym |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $42.33 | 2024-2025 | Rexulti |
| Collegium Pharmaceutical, INC. | $33.09 | 2025 | Jornay Pm |
| Adlon Therapeutics L.P. | $30.06 | 2021 | |
| Jazz Pharmaceuticals INC. | $27.20 | 2022 | |
| Indivior INC. | $26.19 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $24.23 | 2022 | |
| Biogen, INC. | $20.61 | 2024 | Zurzuvae |
| Eisai INC. | $14.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacy Dycus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.